fusion antibodies plc
fusion antibodies plc Company Information
Company Number
NI039740
Next Accounts
Sep 2025
Shareholders
undisclosed
crescent capital ii lp
View AllGroup Structure
View All
Industry
Research and experimental development on biotechnology
+1Registered Address
1 springbank road, springbank industrial estate, belfast, BT17 0QL
Website
www.fusionantibodies.comfusion antibodies plc Estimated Valuation
Pomanda estimates the enterprise value of FUSION ANTIBODIES PLC at £526.6k based on a Turnover of £1.1m and 0.46x industry multiple (adjusted for size and gross margin).
fusion antibodies plc Estimated Valuation
Pomanda estimates the enterprise value of FUSION ANTIBODIES PLC at £0 based on an EBITDA of £-2.1m and a 2.29x industry multiple (adjusted for size and gross margin).
fusion antibodies plc Estimated Valuation
Pomanda estimates the enterprise value of FUSION ANTIBODIES PLC at £3.7m based on Net Assets of £1.8m and 2.04x industry multiple (adjusted for liquidity).
Edit your figures and get a professional valuation report.
Fusion Antibodies Plc Overview
Fusion Antibodies Plc is a live company located in belfast, BT17 0QL with a Companies House number of NI039740. It operates in the research and experimental development on biotechnology sector, SIC Code 72110. Founded in November 2000, it's largest shareholder is undisclosed with a 84% stake. Fusion Antibodies Plc is a mature, small sized company, Pomanda has estimated its turnover at £1.1m with declining growth in recent years.
Upgrade for unlimited company reports & a free credit check
Fusion Antibodies Plc Health Check
Pomanda's financial health check has awarded Fusion Antibodies Plc a 3.5 rating. We use a traffic light system to show it exceeds the industry average on 4 measures and has 7 areas for improvement. Company Health Check FAQs
4 Strong
1 Regular
7 Weak
Size
annual sales of £1.1m, make it smaller than the average company (£2.7m)
£1.1m - Fusion Antibodies Plc
£2.7m - Industry AVG
Growth
3 year (CAGR) sales growth of -35%, show it is growing at a slower rate (10.7%)
-35% - Fusion Antibodies Plc
10.7% - Industry AVG
Production
with a gross margin of -4%, this company has a higher cost of product (50.2%)
-4% - Fusion Antibodies Plc
50.2% - Industry AVG
Profitability
an operating margin of -201.3% make it less profitable than the average company (-1%)
-201.3% - Fusion Antibodies Plc
-1% - Industry AVG
Employees
with 31 employees, this is similar to the industry average (31)
31 - Fusion Antibodies Plc
31 - Industry AVG
Pay Structure
on an average salary of £47.1k, the company has a lower pay structure (£63.8k)
£47.1k - Fusion Antibodies Plc
£63.8k - Industry AVG
Efficiency
resulting in sales per employee of £36.6k, this is less efficient (£117.6k)
£36.6k - Fusion Antibodies Plc
£117.6k - Industry AVG
Debtor Days
it gets paid by customers after 140 days, this is later than average (53 days)
140 days - Fusion Antibodies Plc
53 days - Industry AVG
Creditor Days
its suppliers are paid after 174 days, this is slower than average (43 days)
174 days - Fusion Antibodies Plc
43 days - Industry AVG
Stock Days
it holds stock equivalent to 142 days, this is more than average (40 days)
142 days - Fusion Antibodies Plc
40 days - Industry AVG
Cash Balance
has cash to cover current liabilities for 106 weeks, this is more cash available to meet short term requirements (31 weeks)
106 weeks - Fusion Antibodies Plc
31 weeks - Industry AVG
Debt Level
it has a ratio of liabilities to total assets of 25.9%, this is a lower level of debt than the average (51.4%)
25.9% - Fusion Antibodies Plc
51.4% - Industry AVG
FUSION ANTIBODIES PLC financials
Fusion Antibodies Plc's latest turnover from March 2024 is £1.1 million and the company has net assets of £1.8 million. According to their latest financial statements, Fusion Antibodies Plc has 31 employees and maintains cash reserves of £1.2 million as reported in the balance sheet.
Data source: Companies House, Pomanda Estimates
| Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 | Mar 2015 | Mar 2014 | Mar 2013 | Mar 2012 | Mar 2011 | Mar 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Turnover | 1,136,000 | 2,901,000 | 4,799,000 | 4,165,000 | 3,895,000 | 2,182,000 | 2,690,744 | 1,913,956 | 1,481,265 | 723,046 | 404,997 | 435,213 | 492,293 | 436,947 | |
| Other Income Or Grants | |||||||||||||||
| Cost Of Sales | 1,181,000 | 2,327,000 | 2,333,000 | 2,141,000 | 2,123,000 | 1,378,000 | 1,207,331 | 952,459 | 618,055 | 365,347 | 324,200 | 361,668 | 298,684 | 196,306 | |
| Gross Profit | -45,000 | 574,000 | 2,466,000 | 2,024,000 | 1,772,000 | 804,000 | 1,483,413 | 961,497 | 863,210 | 357,699 | 80,797 | 73,545 | 193,609 | 240,641 | |
| Admin Expenses | 2,242,000 | 3,432,000 | 3,791,000 | 3,273,000 | 2,831,000 | 2,312,000 | 2,193,956 | 834,967 | 835,525 | 477,125 | 554,015 | 841,453 | 804,614 | 1,254,537 | |
| Operating Profit | -2,287,000 | -2,858,000 | -1,325,000 | -1,249,000 | -1,059,000 | -1,508,000 | -710,543 | 126,530 | 27,685 | -119,426 | -473,218 | -767,908 | -611,005 | -1,013,896 | |
| Interest Payable | 5,000 | 4,000 | 9,000 | 18,000 | 20,000 | 4,000 | 4,862 | 615 | 496 | 1,058 | 466 | 601 | 1,092 | 1,471 | |
| Interest Receivable | 3,000 | 3,000 | 1,000 | 3,000 | 6,000 | 13,000 | 4,043 | 1 | 39 | 20 | 152 | 43 | |||
| Pre-Tax Profit | -2,289,000 | -2,859,000 | -1,333,000 | -1,264,000 | -1,073,000 | -1,499,000 | -711,362 | 125,915 | 2,280,995 | -120,483 | -473,645 | -768,489 | -611,945 | -1,015,324 | |
| Tax | 63,000 | 263,000 | 133,000 | -1,635,000 | 376,000 | 235,000 | 11,421 | -5,961 | -1,126,903 | 6,945 | 4,908 | 16,297 | 78,029 | 55,098 | |
| Profit After Tax | -2,226,000 | -2,596,000 | -1,200,000 | -2,899,000 | -697,000 | -1,264,000 | -699,941 | 119,954 | 1,154,092 | -113,538 | -468,737 | -752,192 | -533,916 | -960,226 | |
| Dividends Paid | |||||||||||||||
| Retained Profit | -2,226,000 | -2,596,000 | -1,200,000 | -2,899,000 | -697,000 | -1,264,000 | -699,941 | 119,954 | 1,154,092 | -113,538 | -468,737 | -752,192 | -533,916 | -960,226 | |
| Employee Costs | 1,460,000 | 2,593,000 | 2,455,000 | 2,331,000 | 2,065,000 | 1,512,000 | 1,347,546 | 868,742 | 745,116 | ||||||
| Number Of Employees | 31 | 54 | 58 | 54 | 74 | 38 | 30 | 21 | |||||||
| EBITDA* | -2,068,000 | -2,486,000 | -576,000 | -537,000 | -439,000 | -1,079,000 | -640,918 | 159,520 | 49,921 | -101,093 | -444,749 | -707,619 | -493,737 | -944,160 |
* Earnings Before Interest, Tax, Depreciation and Amortisation
| Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 | Mar 2015 | Mar 2014 | Mar 2013 | Mar 2012 | Mar 2011 | Mar 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tangible Assets | 155,000 | 370,000 | 633,000 | 1,123,000 | 4,998,000 | 2,931,000 | 1,702,781 | 1,226,117 | 1,176,875 | 36,447 | 44,684 | 55,410 | 82,661 | 141,062 | 253,827 |
| Intangible Assets | 3,000 | 5,000 | 2,000 | 4,000 | 6,000 | ||||||||||
| Investments & Other | |||||||||||||||
| Debtors (Due After 1 year) | 1,764,000 | ||||||||||||||
| Total Fixed Assets | 158,000 | 375,000 | 633,000 | 1,125,000 | 3,238,000 | 2,937,000 | 1,702,781 | 1,226,117 | 1,176,875 | 36,447 | 44,684 | 55,410 | 82,661 | 141,062 | 253,827 |
| Stock & work in progress | 460,000 | 539,000 | 585,000 | 480,000 | 340,000 | 243,000 | 81,815 | 70,261 | |||||||
| Trade Debtors | 437,000 | 360,000 | 776,000 | 592,000 | 541,000 | 726,000 | 510,876 | 510,047 | 241,652 | 205,346 | 86,511 | 92,092 | 89,591 | 263,480 | 99,447 |
| Group Debtors | |||||||||||||||
| Misc Debtors | 120,000 | 330,000 | 741,000 | 848,000 | 346,000 | 330,000 | 415,344 | 61,951 | 35,973 | 43,602 | 27,163 | 152,876 | 174,127 | 147,526 | |
| Cash | 1,199,000 | 195,000 | 2,049,000 | 2,686,000 | 1,537,000 | 1,984,000 | 4,490,931 | 285,685 | 413,945 | 103,632 | 139,091 | 129,028 | 45,125 | 126,171 | 318,496 |
| misc current assets | 23,000 | 6,906 | 2,078 | ||||||||||||
| total current assets | 2,262,000 | 1,687,000 | 4,282,000 | 4,705,000 | 2,802,000 | 3,306,000 | 5,505,872 | 930,022 | 691,570 | 308,978 | 269,204 | 248,283 | 287,592 | 563,778 | 565,469 |
| total assets | 2,420,000 | 2,062,000 | 4,915,000 | 5,830,000 | 6,040,000 | 6,243,000 | 7,208,653 | 2,156,139 | 1,868,445 | 345,425 | 313,888 | 303,693 | 370,253 | 704,840 | 819,296 |
| Bank overdraft | 8,624 | ||||||||||||||
| Bank loan | |||||||||||||||
| Trade Creditors | 564,000 | 480,000 | 466,000 | 344,000 | 415,000 | 462,000 | 281,284 | 245,633 | 98,398 | 181,668 | 258,827 | 224,336 | 262,530 | 187,595 | 179,707 |
| Group/Directors Accounts | |||||||||||||||
| other short term finances | 20,000 | 35,000 | 67,000 | ||||||||||||
| hp & lease commitments | 66,000 | 163,000 | 161,000 | 33,758 | |||||||||||
| other current liabilities | 364,000 | 676,000 | 489,000 | 413,000 | 267,000 | 255,015 | 184,584 | 293,032 | 38,741 | 29,229 | 160,199 | 174,354 | 92,315 | ||
| total current liabilities | 584,000 | 879,000 | 1,208,000 | 996,000 | 989,000 | 796,000 | 570,057 | 430,217 | 391,430 | 181,668 | 297,568 | 253,565 | 422,729 | 361,949 | 280,646 |
| loans | 46,000 | 80,000 | 6,000 | 134,000 | 438,000 | 146,000 | 87,058 | ||||||||
| hp & lease commitments | 3,000 | 67,000 | 219,000 | 43,529 | 3,919 | ||||||||||
| Accruals and Deferred Income | |||||||||||||||
| other liabilities | |||||||||||||||
| provisions | 40,000 | 40,000 | 40,000 | 40,000 | 40,000 | 40,000 | 40,000 | 40,000 | 40,000 | 20,000 | 20,000 | 20,000 | 20,000 | 20,000 | 20,000 |
| total long term liabilities | 43,000 | 60,000 | 23,000 | 87,000 | 239,000 | 93,000 | 63,529 | 20,000 | 20,000 | 20,000 | 20,000 | 20,000 | 20,000 | 20,000 | 23,919 |
| total liabilities | 627,000 | 939,000 | 1,231,000 | 1,083,000 | 1,228,000 | 889,000 | 633,586 | 450,217 | 411,430 | 201,668 | 317,568 | 273,565 | 442,729 | 381,949 | 304,565 |
| net assets | 1,793,000 | 1,123,000 | 3,684,000 | 4,747,000 | 4,812,000 | 5,354,000 | 6,575,067 | 1,705,922 | 1,457,015 | 143,757 | -3,680 | 30,128 | -72,476 | 322,891 | 514,731 |
| total shareholders funds | 1,793,000 | 1,123,000 | 3,684,000 | 4,747,000 | 4,812,000 | 5,354,000 | 6,575,067 | 1,705,922 | 1,457,015 | 143,757 | -3,680 | 30,128 | -72,476 | 322,891 | 514,731 |
| Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 | Mar 2015 | Mar 2014 | Mar 2013 | Mar 2012 | Mar 2011 | Mar 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | |||||||||||||||
| Operating Profit | -2,287,000 | -2,858,000 | -1,325,000 | -1,249,000 | -1,059,000 | -1,508,000 | -710,543 | 126,530 | 27,685 | -119,426 | -473,218 | -767,908 | -611,005 | -1,013,896 | |
| Depreciation | 219,000 | 372,000 | 749,000 | 712,000 | 620,000 | 429,000 | 69,625 | 32,990 | 22,236 | 19,435 | 18,333 | 28,469 | 60,289 | 117,268 | 69,736 |
| Amortisation | |||||||||||||||
| Tax | 63,000 | 263,000 | 133,000 | -1,635,000 | 376,000 | 235,000 | 11,421 | -5,961 | -1,126,903 | 6,945 | 4,908 | 16,297 | 78,029 | 55,098 | |
| Stock | -79,000 | -46,000 | 105,000 | 140,000 | 97,000 | 161,185 | 11,554 | 70,261 | |||||||
| Debtors | -133,000 | -827,000 | 77,000 | -1,211,000 | 1,595,000 | 129,780 | 354,222 | 294,373 | 72,279 | 75,233 | 10,858 | -123,212 | -195,140 | 190,634 | 246,973 |
| Creditors | 84,000 | 14,000 | 122,000 | -71,000 | -47,000 | 180,716 | 35,651 | 147,235 | -83,270 | -77,159 | 34,491 | -38,194 | 74,935 | 7,888 | 179,707 |
| Accruals and Deferred Income | -364,000 | -312,000 | 187,000 | 76,000 | 146,000 | 11,985 | 70,431 | -108,448 | 293,032 | -38,741 | 9,512 | -130,970 | -14,155 | 82,039 | 92,315 |
| Deferred Taxes & Provisions | 20,000 | 20,000 | |||||||||||||
| Cash flow from operations | -2,073,000 | -1,648,000 | -316,000 | -1,096,000 | -1,656,000 | -942,264 | -889,191 | -172,288 | -919,499 | -61,003 | -485,793 | -435,402 | -516,415 | -844,013 | |
| Investing Activities | |||||||||||||||
| capital expenditure | |||||||||||||||
| Change in Investments | |||||||||||||||
| cash flow from investments | |||||||||||||||
| Financing Activities | |||||||||||||||
| Bank loans | |||||||||||||||
| Group/Directors Accounts | |||||||||||||||
| Other Short Term Loans | -15,000 | 35,000 | -67,000 | 67,000 | |||||||||||
| Long term loans | -34,000 | 74,000 | -128,000 | -304,000 | 292,000 | 58,942 | 87,058 | ||||||||
| Hire Purchase and Lease Commitments | -69,000 | -161,000 | -150,000 | 380,000 | -77,287 | 77,287 | -3,919 | 3,919 | |||||||
| other long term liabilities | |||||||||||||||
| share issue | |||||||||||||||
| interest | -2,000 | -1,000 | -8,000 | -15,000 | -14,000 | 9,000 | -819 | -615 | -496 | -1,057 | -427 | -581 | -940 | -1,428 | |
| cash flow from financing | 2,845,000 | 74,000 | -160,000 | 2,365,000 | 746,000 | 100,588 | 5,732,612 | 128,338 | 158,670 | 78,673 | 570,914 | 356,244 | 337,217 | 1,477,448 | |
| cash and cash equivalents | |||||||||||||||
| cash | 1,004,000 | -1,854,000 | -637,000 | 1,149,000 | -447,000 | -2,506,931 | 4,205,246 | -128,260 | 310,313 | -35,459 | 10,063 | 83,903 | -81,046 | -192,325 | 318,496 |
| overdraft | -8,624 | 8,624 | |||||||||||||
| change in cash | 1,004,000 | -1,854,000 | -637,000 | 1,149,000 | -447,000 | -2,506,931 | 4,205,246 | -128,260 | 310,313 | -35,459 | 10,063 | 83,903 | -81,046 | -183,701 | 309,872 |
fusion antibodies plc Credit Report and Business Information
Fusion Antibodies Plc Competitor Analysis
Perform a competitor analysis for fusion antibodies plc by selecting its closest rivals, whether from the PROFESSIONAL, SCIENTIFIC AND TECHNICAL ACTIVITIES sector, other small companies, companies in BT17 area or any other competitors across 12 key performance metrics.
fusion antibodies plc Ownership
FUSION ANTIBODIES PLC group structure
Fusion Antibodies Plc has no subsidiary companies.
Ultimate parent company
FUSION ANTIBODIES PLC
NI039740
fusion antibodies plc directors
Fusion Antibodies Plc currently has 7 directors. The longest serving directors include Prof John Cadogan (Mar 2005) and Dr Simon Douglas (Sep 2006).
| officer | country | age | start | end | role |
|---|---|---|---|---|---|
| Prof John Cadogan | 94 years | Mar 2005 | - | Director | |
| Dr Simon Douglas | England | 66 years | Sep 2006 | - | Director |
| Mr Colin Walsh | Northern Ireland | 69 years | Jul 2007 | - | Director |
| Dr Richard Buick | Northern Ireland | 48 years | Aug 2011 | - | Director |
| Mr Matthew Baker | United Kingdom | 54 years | Mar 2022 | - | Director |
| Dr Adrian Kinkaid | England | 58 years | Aug 2022 | - | Director |
| Mr Stephen Smyth | Northern Ireland | 50 years | Sep 2023 | - | Director |
P&L
March 2024turnover
1.1m
-61%
operating profit
-2.3m
-20%
gross margin
-3.9%
-120.02%
turnover
Turnover, or revenue, is the amount of sales generated by a company within the financial year.
Balance Sheet
March 2024net assets
1.8m
+0.6%
total assets
2.4m
+0.17%
cash
1.2m
+5.15%
net assets
Total assets minus all liabilities
Similar Companies
fusion antibodies plc company details
company number
NI039740
Type
Public limited with Share Capital
industry
72110 - Research and experimental development on biotechnology
74909 - Other professional, scientific and technical activities (not including environmental consultancy or quantity surveying) n.e.c.
incorporation date
November 2000
age
25
incorporated
UK
ultimate parent company
accounts
Full Accounts
last accounts submitted
March 2024
previous names
fusion antibodies limited (December 2017)
accountant
-
auditor
KRESTON REEVES LLP
address
1 springbank road, springbank industrial estate, belfast, BT17 0QL
Bank
DANSKE BANK
Legal Advisor
TUGHANS DLA PIPER UK LLP
fusion antibodies plc Charges & Mortgages
A charge, or mortgage, refers to the rights a company gives to a lender in return for a loan, often in the form of security given over business assets.
We found 5 charges/mortgages relating to fusion antibodies plc. Currently there are 2 open charges and 3 have been satisfied in the past.
fusion antibodies plc Capital Raised & Share Issues BETA
When a company issues new shares, e.g. to new investors following a funding round, it is required to notify Companies House within one month of making an allotment of shares.
Click to start generating capital raising & share issue transactions for FUSION ANTIBODIES PLC. This can take several minutes, an email will notify you when this has completed.
fusion antibodies plc Companies House Filings - See Documents
| date | description | view/download |
|---|
